Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Evolving treatment landscape of DLBCL

Gerardo Musuraca • 17 Sep 2020
SOHO Italy 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Gerardo Musuraca, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the changing treatment landscape of diffuse large B-cell lymphoma (DLBCL), and how this is guided by a greater molecular understanding of disease biology and pathogenesis. Dr Musuraca also highlights biological agents that have been developed for the different molecular subtypes of DLBCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Gerardo Musuraca

2:29
The management of DLBCL and the importance of characterizing molecular subtypes
Gerardo Musuraca • 24 Oct 2022
1:12
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Gerardo Musuraca • 24 Oct 2022
2:19
Italian perspective: managing DLBCL
Gerardo Musuraca • 17 Sep 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals